Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28822391 | 0.91 | ADORA3 (0.48) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL8606010 | 0.90 | SLC28A1 (0.53) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL8608410 | 0.88 | SLC28A1 (0.53) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL120550 | 0.85 | ADORA3 (0.51) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL10689174 | 0.85 | ADORA3 (0.53) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL120561 | 0.84 | ADORA3 (0.50) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL8608416 | 0.83 | ADORA3 (0.47) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL8608777 | 0.82 | ADORA3 (0.50) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL10699083 | 0.82 | ADORA3 (0.48) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B | |
| SCHEMBL2372382 | 0.81 | ADORA2A (0.49) | ADORA3ADORA2AADORA1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125779-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-02 | — | — | US | claimed |
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | claimed |
| US-20170042929-A9 | Methods of Treating Neurological Diseases | UNIVERSITY OF HOUSTON | 2017-02-16 | — | — | US | claimed |
| WO-2016109624-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-07-07 | — | — | WO | claimed |
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | claimed |
| WO-2016090005-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-06-09 | — | — | WO | claimed |
| EP-2968388-A1 | A METHOD OF PROVIDING OCULAR NEUROPROTECTION | Inotek Pharmaceuticals Corporation (US) | 2016-01-20 | — | — | EP | claimed |
| US-20150051166-A1 | Methods of Treating Neurological Diseases | ZIBURKUS JOKUBAS (US) | 2015-02-19 | — | — | US | claimed |
| WO-2014152733-A1 | A METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-18 | — | — | US | claimed |
| WO-2014028883-A1 | METHODS OF TREATING OF NEUROLOGICAL DISEASES | UNIVERSITY OF HOUSTON (US) | 2014-02-20 | — | — | WO | claimed |
| US-20130005676-A1 | ENHANCING THE THERAPEUTIC EFFECT OF ACUPUNCTURE WITH ADENOSINE | UNIVERSITY OF ROCHESTER (US) | 2013-01-03 | — | — | US | claimed |
| EP-2504347-A1 | ENHANCING THE THERAPEUTIC EFFECT OF ACUPUNCTURE WITH ADENOSINE | University Of Rochester (US) | 2012-10-03 | — | — | EP | claimed |
| WO-2011066412-A1 | ENHANCING THE THERAPEUTIC EFFECT OF ACUPUNCTURE WITH ADENOSINE | UNIVERSITY OF ROCHESTER (US) | 2011-06-03 | — | — | WO | claimed |
| US-20100284984-A1 | ADENOSINE AND ITS MIMETICS. MODULATORS, TRANSPORT INHIBITORS, AND RECEPTOR AGONISTS AS A THERAPEUTIC TOOL TO REPLACE OR IMPROVE THE EFFICACY OF DEEP BRAIN STIMULATION | UNIVERSITY OF ROCHESTER (US) | 2010-11-11 | — | — | US | claimed |
| EP-2180916-A1 | ADENOSINE AND ITS MIMETICS, MODULATORS, TRANSPORT INHIBITORS, AND RECEPTOR AGONISTS AS A THERAPEUTIC TOOL TO REPLACE OR IMPROVE THE EFFICACY OF DEEP BRAIN STIMULATION | University Of Rochester (US) | 2010-05-05 | — | — | EP | claimed |
| WO-2009018275-A1 | ADENOSINE AND ITS MIMETICS, MODULATORS, TRANSPORT INHIBITORS, AND RECEPTOR AGONISTS AS A THERAPEUTIC TOOL TO REPLACE OR IMPROVE THE EFFICACY OF DEEP BRAIN STIMULATION | UNIVERSITY OF ROCHESTER (US) | 2009-02-05 | — | — | WO | claimed |
| EP-0996453-B1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 2004-04-28 | — | — | EP | claimed |
| US-20190125779-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-02 | — | — | US | disclosed |
| WO-1998058653-A1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | ADORA2A, ADORA1, PDE6C | ADORA3 4/4885ADORA2A 1/4885SLC28A1 411/4885 |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | ALDH1A2, GAP43, ALDH1A3 | ADORA3 226/4885ADORA2A 24/4885SLC28A1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.